Home > E. Pathology by systems > Nervous system > Central nervous system > Brain > glioblastoma
glioblastoma
Saturday 6 November 2004
Loss of heterozygosity (Allelotyping) (12875726)
| 3q25.2-26.2 LOH | |||
| 4q31.1-31.2 LOH | |||
| 4q35 LOH | |||
| 6q21-23.3 LOH | |||
| 6q27 LOH | |||
| 9p21-23 LOH | 31% | CDKN2A (p16) | CDKN2B (p15) |
| 9q LOH | |||
| 10p12.2-14 LOH | |||
| 10q LOH | 69% | ||
| 10q21.3 LOH | |||
| 10q23 LOH | 24%-69% | PTEN | |
| 10q25.3-q26.1 LOH | DMBT1 | ||
| 11p12-13 LOH | |||
| 13q12.1-14.1 LOH | |||
| 13q14.3-31 LOH | RB | ||
| 14q11.1-13 LOH | |||
| 14q13-31 LOH | |||
| 14q32.1 LOH | |||
| Chr.15 LOH | |||
| 17p11.2-12 LOH | |||
| 17p13 LOH | 31% | TP53 | |
| 19q LOH | |||
| 22q13.3 LOH |
Gene inactivations
| TP53 | 31% | 17p13 |
| CDKN2A (p16) | 31% | 9p21 |
| PTEN | 24% | 10q23 |
Glioblastomas frequently carry mutations in the PTEN tumor suppressor gene on 10q23.3 (24%).
Gene overexpressions
EGFR amplification (34%)
Amplified regions and gene copy increases (chromosome gains, genic amplifications)
Chr.7 (radiation resistance) (16130123)
Chr.1
Chr.4
Chr.11
Chr.12
Molecular pathways
genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3’-kinase/protein kinase B (Akt) signal transduction pathway in glioblastoma (14655756)
Variants
epithelioid glioblastoma
primary glioblastoma (de novo) prevailed (95%)
secondary glioblastoma
References
Ohgaki H. Genetic pathways to glioblastomas. Neuropathology. 2005 Mar;25(1):1-7. PMID: 15822813
References
Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007 Oct;7(10):733-6. PMID: 17882276
Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3’-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 2003 Oct;13(4):507-18. PMID: 14655756
